Relationship between malignant subtypes of meningioma and clinical outcome.

J Clin Neurosci

Department of Neurosurgery, Samsung Medical Center and Samsung Biomedical Research Institute, SungKyunKwan University School of Medicine, 50 Ilwon-Dong, Kangnam-ku, Seoul 135-710, Korea.

Published: August 2007

We evaluated the relationship between histological malignant subtypes (WHO grade II or III) of meningioma and clinical outcome. Of 485 patients treated surgically for intracranial meningioma at our hospital between 1994 and 2004, 49 (10%; 18 male, 31 female) had potentially malignant features. The histological tumor subtypes within this group of patients included: atypical (n=23); clear cell (n=3); chordoid (n=5); rhabdoid (n=16); and anaplastic (n=4). Correlations among prognosis, recurrence, and the following factors were analyzed for each histological subtype: the Simpson grade of surgical resection (grades I-III vs. grade IV), tumor location (convexity vs. other), the Ki-67 index, and use of postoperative radiotherapy. The median value of the Ki-67 index was 16.2% (range: 1.0-57.2%). The surgical resections were of Simpson grades I-III and IV in 43 and six of the 49 patients, respectively. Tumors recurred after the initial surgical resection in 14 of the 49 patients. In view of the relatively high proportion of malignant subtypes (10%), we suggest that all meningiomas should be evaluated for malignancy. The extent of surgical resection, the histological subtype, and the Ki-67 index can help to predict the clinical outcome for meningioma patients.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jocn.2006.05.005DOI Listing

Publication Analysis

Top Keywords

malignant subtypes
12
clinical outcome
12
surgical resection
12
meningioma clinical
8
histological subtype
8
grades i-iii
8
patients
5
relationship malignant
4
subtypes
4
meningioma
4

Similar Publications

CD4FOXP3Exon2 regulatory T cell frequency predicts breast cancer prognosis and survival.

Sci Adv

January 2025

Istituto per l'Endocrinologia e l'Oncologia Sperimentale "G. Salvatore", IEOS-CNR, Napoli, Italy.

CD4FOXP3 regulatory T cells (T) suppress immune responses to tumors, and their accumulation in the tumor microenvironment (TME) correlates with poor clinical outcome in several cancers, including breast cancer (BC). However, the properties of intratumoral T remain largely unknown. Here, we found that a functionally distinct subpopulation of T, expressing the FOXP3 Exon2 splicing variants, is prominent in patients with hormone receptor-positive BC with poor prognosis.

View Article and Find Full Text PDF

Background: The prognosis of patients with advanced soft tissue sarcoma (STS) remains dismal. Trofosfamide (TRO) has been proposed as a well-tolerated oral maintenance therapy. This retrospective analysis aims to determine the value of this therapy.

View Article and Find Full Text PDF

Background And Purpose: We report the incidence, characteristics, and comorbidities of the complete unselected Danish cohort of patients with thymic epitheliums (TETs), which may serve as evidence for guiding treatment, surveillance, and counselling of TET patients.

Patients And Methods: All patients diagnosed with TETs from January 1st, 2015, to December 31st, 2020, were identified using the Danish Pathology Data Registry. Data on patient characteristics, comorbidities, and tumor histology were collected from electronic medical records available for all patients.

View Article and Find Full Text PDF

Breast cancer is the most common cancer among women, with over 1 million new cases and around 400,000 deaths annually worldwide. This makes it a significant and costly global health challenge. Standard treatments like chemotherapy and radiotherapy, often used after mastectomy, show varying effectiveness based on the cancer subtype.

View Article and Find Full Text PDF

Introduction: Immunoglobulin D (IgD) myeloma is a rare subtype often described as aggressive with advanced disease at diagnosis. Primary renal involvement is seen in scarce cases.

Observation: This case features a 55-year-old man with IgD lambda myeloma presenting severe renal failure at diagnosis.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!